Aerie Pharmaceuticals recently announced the FDA approval of Rhopressa, a first-in-class therapy for the treatment of patients with open-angle glaucoma and other diseases of the eye.
Rhopressa (netarsudil ophthalmic solution 0.02%) is a once-daily eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension. The drop was approved by the FDA ahead of the scheduled Prescription Drug User Fee Act date of Feb. 28, 2018, according to a company release.
The therapy is believed to reduce IOP by increasing outflow of aqueous humor through the trabecular (Read more...)
Uncategorized